Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy

References

• Vaughn JE, Buckley SA, Walter RB. Outpatient care of patients with acute myeloid leukemia: benefits, barriers, and future considerations. Leuk Res. 2016;45:53–58.
   PubMed Web of Science ®Google Scholar
• Halpern AB, Walter RB, Estey EH. Outpatient induction and consolidation care strategies in acute myeloid leukemia. Curr Opin Hematol. 2019; 26(2):65–70.
   PubMed Web of Science ®Google Scholar
• Halpern AB, Walter RB. Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings. Hematology Am Soc Hematol Educ Program. 2020;2020(1):129–134.
   PubMedGoogle Scholar
• Walter RB, Lee SJ, Gardner KM, et al. Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. Haematologica. 2011;96(6):914–917.
   PubMed Web of Science ®Google Scholar
• Vaughn JE, Othus M, Powell MA, et al. Resource utilization and safety of outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia or myelodysplastic syndrome: a nonrandomized clinical comparative analysis. JAMA Oncol. 2015;1(8):1120–1127.
   PubMed Web of Science ®Google Scholar
• Halpern AB, Howard NP, Othus M, et al. Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. Leukemia. 2020;34(2):635–639.
   PubMed Web of Science ®Google Scholar
• Moore NJ, Othus M, Halpern AB, et al. Financial implications of early hospital discharge following acute myeloid leukemia-like induction chemotherapy: a 4-year retrospective analysis. J Natl Compr Canc Netw. 2021. in press.
   Google Scholar
• Halpern AB, Othus M, Howard NP, et al. Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. Leuk Lymphoma. 2021;62(1):234–238.
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.
   PubMedGoogle Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the european LeukemiaNet. Blood. 2010;115(3):453–474.
   PubMed Web of Science ®Google Scholar
• Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367–1376.
   PubMed Web of Science ®Google Scholar
• Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417–4423.
   PubMed Web of Science ®Google Scholar
• Safdar N, Maki DG. Risk of catheter-related bloodstream infection with peripherally inserted Central venous catheters used in hospitalized patients. Chest. 2005;128(2):489–495.
   PubMed Web of Science ®Google Scholar
• Skaff ER, Doucette S, McDiarmid S, et al. Vascular access devices in leukemia: a retrospective review amongst patients treated at the ottawa hospital with induction chemotherapy for acute leukemia. Leuk Lymphoma. 2012;53(6):1090–1095.
   PubMed Web of Science ®Google Scholar
• Chopra V, O’Horo JC, Rogers MAM, et al. The risk of bloodstream infection associated with peripherally inserted Central catheters compared with Central venous catheters in adults: a systematic review and Meta-analysis. Infect Control Hosp Epidemiol. 2013;34(9):908–918.
   PubMed Web of Science ®Google Scholar
• Picardi M, Della Pepa R, Cerchione C, et al. A frontline approach with peripherally inserted versus centrally inserted Central venous catheters for remission induction chemotherapy phase of acute myeloid leukemia: a randomized comparison. Clin Lymphoma Myeloma Leuk. 2019;19(4):e184–e194.
   PubMed Web of Science ®Google Scholar
• McDonald MK, Culos KA, Gatwood KS, et al. Defining incidence and risk factors for catheter-associated bloodstream infections in an outpatient adult hematopoietic cell transplantation program. Biol Blood Marrow Transplant. 2018;24(10):2081–2087.
   PubMed Web of Science ®Google Scholar
• Luft D, Schmoor C, Wilson C, et al. Central venous catheter-associated bloodstream infection and colonisation of insertion site and catheter tip. What are the rates and risk factors in haematology patients? Ann Hematol. 2010;89(12):1265–1275.
   PubMed Web of Science ®Google Scholar
• Hentrich M, Schalk E, Schmidt-Hieber M, et al. Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the infectious diseases working party of the German society of hematology and medical oncology. Ann Oncol. 2014;25(5):936–947.
   PubMed Web of Science ®Google Scholar
• Baier C, Linke L, Eder M, et al. Incidence, risk factors and healthcare costs of Central line-associated nosocomial bloodstream infections in hematologic and oncologic patients. PLoS One. 2020;15(1):e0227772.
   PubMed Web of Science ®Google Scholar
• Carratalà J, Niubó J, Fernández-Sevilla A, et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive Central venous catheter-related infection in neutropenic patients with cancer. Antimicrob Agents Chemother. 1999;43(9):2200–2204.
   PubMed Web of Science ®Google Scholar
• Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med. 2013;368(6):533–542.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359.
   PubMed Web of Science ®Google Scholar
• O'Sullivan AK, Pandya A, Papadopoulos G, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health. 2009;12(5):666–673.
   PubMed Web of Science ®Google Scholar
• Sung AH, Marcella SW, Xie Y. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States. J Med Econ. 2015;18(5):341–348.
   PubMed Web of Science ®Google Scholar